There is now conclusive and reassuring evidence of the cannnabis-based treatment Sativex’s tolerability and effectiveness in reducing spasticity and related symptoms in multiple sclerosis, according to studies reported at the ECTRIMS/ACTRIMS meeting in Amsterdam.
Read MoreAccording to the latest Phase III data, Grunenthal’s novel analgesic tapentadol provides comparable pain relief to the standard opioid oxycodone, but with less likelihood of gastrointestinal side effects such as nausea, vomiting and constipation. The results were presented at the 12th World Congress on Pain in Glasgow.
Read MoreGrunenthal’s Versatis plaster relieves pain as effectively as oral treatment with Pfizer’s Lyrica but with fewer side-effects, according to results presented at the 12th World Congress on Pain in Glasgow.
Read More
